CLXR-901 / Celexor Bio - LARVOL DELTA

Aditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory Disorders (BioSpace) - "Aditum Bio...today announced the formation of Celexor Bio, a portfolio company created for the development of novel therapies for inflammatory disorders. Celexor Bio is being formed in connection with the in-licensing of a depleting antibody targeting immunoglobulin-like transcript 7 (ILT7), a highly specific cell surface marker found on plasmacytoid dendritic cells (pDCs), which is anticipated to close later this month. The compound (IMG-018) is being licensed from Inmagene Biopharmaceuticals and will be renamed CLXR-901."

Licensing / partnership • Immunology